Atherosclerosis Cerebral Infarction Clinical Trial
Official title:
A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject
| Verified date | January 2010 |
| Source | Otsuka Beijing Research Institute |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | China: Food and Drug Administration |
| Study type | Interventional |
Randomized, control, open label, multicentre clinical study. The patient who are in accordance with subject inclusion and exclusion criteria will be randomized to A group: Routine treatment B group: Routine treatment+ Cilostazol; C group : Routine treatment + Probucol; D group: Routine treatment+ Cilostazol+ Probucol .
| Status | Completed |
| Enrollment | 200 |
| Est. completion date | July 2010 |
| Est. primary completion date | December 2009 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 40 Years to 80 Years |
| Eligibility |
Inclusion Criteria: 1. 40~80-year-old male or female 2. By brain CT or MRI result, cerebral infarction is clarified diagnosis within 1 year 3. With atherosclerosis, atherosclerosis should meet at least one of the conditions as below: - Clarified diagnosis of type 2 diabetes before - Clarified diagnosis of primary hypertension before - Clarified diagnosis of Atherosclerotic stenosis in any 2 or more than 2 regions as cerebral artery, carotid, extremity artery and coronary by conformation of ultrasonic or angiography result 4. Has Aspirin regularly for more than 1 month before registration 5. Informed Consent Form signature Exclusion criteria: 1. Has an allergic history to study drugs( including of Probucol and Cilostazol) and Aspirin 2. Had lipid-lowing agents within the last 3 months ( except Statins) 3. Had antiplatelet or anticoagulation agents within the last 3 months (except Aspirin) 4. Had acute cerebral infarction within the last 1 month 5. Has cardiogenic cerebral embolism 6. At the registration ,Modified Rankin Scale = 4 7. Hemorrhagic tendency or hemorrhagic disease (such as cerebral hemorrhage, gastrointestinal tract hemorrhage, etc.) 8. Had a myocardial infarction, angina pectoris within the last 3 months 9. Congestive heart failure 10. Is pregnant, is potentially pregnant, or is breastfeeding 11. Severe hepatic inadequacy or severe renal inadequacy (AST or ALT is 2.5 times higher than the upper limit of the normal value range, or serum creatinine is 1.2 times higher than the upper limit of the normal value range) 12. Persistent or hardly controlled hypertension (such as malignant hypertension, BP> 160/100 mmHg) 13. Severe ventricular arrhythmia (such as multiple and multifocal premature ventricular contractions) 14. Has a medical history that includes a cardiac syncope or a primary syncope 15. Has a condition that may prolong QT interval (such as congenital long QT syndrome, taking drugs which prolong QT interval, hypokalemia or hypomagnesemia, etc.) 16. Has severe diseases (such as, malignant tumor, severe anaemia, severe hematologic diabetes mellitus ketoacidosis, nonketotic hyperosmolar diabetic coma, etc.) 17. Registered other clinical trails within the last 3 months 18. Has vasculitis, moyamoya disease and other non-atherosclerosis vascular diseases 19. Other conditions that could exclude the subject from this study by doctor's judgment |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| China | First Affliate Hospital of Beijing University | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Otsuka Beijing Research Institute |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | After 12 weeks of treatment, the change difference of arteriosclerosis related biomarker between 4 modality groups. | 12 week | No |